Alemtuzumab Approved For Multiple Sclerosis

The FDA has approved alemtuzumab (Lemtrada) as a treatment for patients with multiple sclerosis. The FDA was careful to cite that use of alemtuzumab was a high-risk option since the drug may cause an increased risk for malignancies, including thyroid cancer, melanoma, lymphoproliferative disorders, neuropathy, which in some instances proved fatal. The medication is also marketed as Campath, which … Continue reading Alemtuzumab Approved For Multiple Sclerosis